A Relative Bioavailability Food Effect Study of LY03005

NCT03822065 | Completed Phase 1 FDA Drug

• 1 other identifier: LY03005/CT-USA-105
• Study Type: interventional
• Target: 34
• Locations: 1 country
• Sites: 1

Brief Summary

The objective if this study is to assess the relative bio-availability of single oral doses of 80 mg LY03005 tablets administered to healthy subjects under fed versus fasted conditions in a 2-period, crossover trial.

Conditions

Major Depressive Disorder

Keywords

Depressive Disorder, Major; Depressive Disorder; Mood Disorders; Mental Disorders; Desvenlafaxine Succinate; Serotonin and Noradrenaline Reuptake Inhibitors; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action; Neurotransmitter Agents; Physiological Effects of Drugs; Antidepressive Agents; Psychotropic Drugs

Outcome Measures

Primary Outcomes (2)

• Pharmacokinetic Parameters

  Area under the concentration-time curve (AUC)

  PK samples drawn at predose (within 30 minutes prior to dosing) and at 1, 2, 3, 4 (±5 minutes), 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours (±15 minutes) after the dose.

• Pharmacokinetic Parameters

  Maximum concentration (Cmax) for the Pharmacokinetics (PK) of O-desmethyl-venlafaxine (ODV) from LY03005

  PK samples drawn at predose (within 30 minutes prior to dosing) and at 1, 2, 3, 4 (±5 minutes), 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours (±15 minutes) after the dose.

Study Arms (2)

Sequence 1: LY03005 Fed Crossover to Fasted

EXPERIMENTAL

Sequence 1 will receive a single oral dose of LY03005 (80 mg) under fed conditions in Treatment Period 1 and a single oral dose of LY03005 (80 mg) under fasted conditions in Treatment Period 2.

Drug: LY03005

Sequence 2: LY03005 Fasted Crossover to Fed

EXPERIMENTAL

Sequence 2 will receive a single oral dose of LY03005 (80 mg) under fasted conditions in Treatment Period 1 and a single oral dose of LY03005 (80 mg) under fed conditions in Treatment Period 2.

Drug: LY03005

Interventions

LY03005 DRUG

80 mg oral tablet single dose

Also known as: Desvenlafaxine

Sequence 1: LY03005 Fed Crossover to Fasted; Sequence 2: LY03005 Fasted Crossover to Fed

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Capable of giving informed consent and complying with trial procedures;
• Male and female subjects between the ages of 18 and 50 years, inclusive;
• Considered healthy by the Investigator based on a detailed medical history, full physical examination, clinical laboratory tests, 12-lead ECG, and vital signs;
• Nonsmoker, defined as not having smoked or used any form of tobacco for at least 6 months before Screening based on subject report;
• Body mass index (BMI) of 19 to 30 kg/m2 inclusive and body weight \>/= 50 kg;
• Willing and able to adhere to trial procedures and to be confined at the clinical research unit (CRU).
• All female subjects (childbearing potential and non-childbearing potential) must have a negative serum pregnancy test result at Screening. In addition, female subjects must meet 1 of the following 3 conditions: (a) postmenopausal for at least 12 months without an alternative medical cause, (ii) surgically sterile (hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal occlusion) based on subject report, or (iii) if of childbearing potential and heterosexually active, practicing or agree to practice a highly effective method of contraception. Highly effective methods of birth control include an intrauterine device (IUD), intrauterine hormone-releasing system (IUS), and contraceptives (oral, skin patches, or implanted or injectable products) using combined or progestogen-only hormonal contraception associated with inhibition of ovulation. A vasectomized male partner is an acceptable birth control method if the vasectomized partner is the sole sexual partner of the female subject and the vasectomized partner has received medical confirmation of surgical success. Highly effective methods of birth control must be used for at least 14 days prior to study drug dosing, through the end of study (EOS) visit or early termination, and for a minimum of 1 month after the last dose of study drug to minimize the risk of pregnancy. Sexually active, fertile, male subjects must be willing to use acceptable contraception methods (such as double-barrier methods of a combination of male condom with either cap, diaphragm, or sponge with spermicide) from the first dose of study drug through the EOS visit or early termination, and for a minimum of 1 month after the last dose of study drug.

You may not qualify if:

• Clinically significant past medical history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric (including life-long history of depression and/or anxiety), renal, hepatic, bronchopulmonary, neurologic, immunologic, ophthalmological, or lipid metabolism disorders; or drug hypersensitivity; or any condition that in the judgement of the Investigator will affect the trial results or the subject's safety;
• History of suicide attempt in the past 12 months and/or seen by the Investigator as having a significant history of risk of suicide or homicide;
• History or presence of malignancy other than adequately treated and cured basal cell skin cancer, squamous cell skin cancer, or in-situ cervical cancer, within 5 years prior to screening;
• Clinically relevant illness within 1 month prior to Screening or at Screening that may interfere with the conduct of this trial;
• Medically uncontrolled high blood pressure with mean systolic blood pressure \>140 mmHg or mean diastolic blood pressure \>90 mmHg at Screening after 3 measurements (after at least 5 minutes of rest in a seated position);
• History of Long QT Syndrome (LQTS) or a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \>450 ms);
• Positive blood screen for HIV, hepatitis B surface antigen (HBsAg), or hepatitis C antibody;
• History of seizure (history of febrile seizure allowed);
• Hospital admission or major surgery within 30 days prior to Screening;
• Participation in any other investigational drug trial within 30 days prior to Screening;
• History of prescription drug abuse or illicit drug use within 6 months prior to Screening;
• History of alcohol abuse according to medical history within 6 months prior to Screening;
• Positive screen for alcohol and/or drugs of abuse;
• Tobacco use within 6 months prior to Screening based on subject report or positive nicotine screen;
• History of intolerance or hypersensitivity to ODV or medicines containing ODV or its precursor venlafaxine;

Sponsors & Collaborators

• Luye Pharma Group Ltd.: lead

Study Sites (1)

Pharmaron CPC, Inc.

Baltimore, Maryland, 21201, United States

Location

Related Links

• Drug information
• Desvenlafaxine
• Desvenlafaxine Succinate
• U.S. FDA Resources

MeSH Terms

Conditions

Depressive Disorder, Major; Depressive Disorder; Mood Disorders; Mental Disorders

Interventions

Desvenlafaxine Succinate

Intervention Hierarchy (Ancestors)

Cyclohexanols; Hexanols; Fatty Alcohols; Alcohols; Organic Chemicals; Cyclohexanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Lipids

Study Officials

• Kevin Booth, MD, DVM

  Luye Pharma.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 25, 2019
• First Posted: January 30, 2019
• Study Start: January 16, 2019
• Primary Completion: February 16, 2019
• Study Completion: February 16, 2019
• Last Updated: August 6, 2019

Record last verified: 2019-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)